Glycorex Transplantation Aktiebolag (O33)

Overview

Glycorex Transplantation AB (publ) is a pioneering medical technology company based in Lund, Sweden, founded in 1996. The company specializes in the development, production, and sale of innovative products designed to improve the outcomes of organ transplantation. Utilizing a molecular level nanosurgical technology, Glycorex Transplantation focuses on the selective removal of antibodies in the blood that can complicate transplants, blood transfusions, blood products, and the treatment of autoimmune diseases. It plays a crucial role in enhancing the compatibility of organ transplants across blood group barriers, thereby opening up new possibilities for patients awaiting life-saving transplant procedures. With a significant presence in Europe, including Austria, France, Germany, the Netherlands, and Spain, Glycorex Transplantation is at the forefront of addressing the complex challenges associated with organ transplantation.

Products and Services

• Glycosorb-ABO

This flagship product represents a breakthrough in the field of organ transplantation. Glycosorb-ABO is designed to facilitate the transplantation of organs across blood group barriers, which has historically been a significant challenge. By selectively removing blood group specific antibodies, Glycosorb-ABO allows for kidney, liver, heart, lung, pancreatic, and stem cell transplantation procedures between donors and recipients of incompatible blood types. This technology not only expands the donor pool but also significantly improves patient outcomes by reducing the risks associated with antibody-mediated rejection.

• Glycosorb UBP

An advanced tool for the treatment of donor blood, Glycosorb UBP is engineered to enhance the safety and efficacy of blood transfusions. It is specifically designed for the processing of universal blood donor plasma, removing antibodies that can cause adverse reactions in recipients. This product ensures that blood transfusions are safer and more compatible, minimizing the risk of transfusion-related complications. Glycosorb UBP represents Glycorex Transplantation's commitment to advancing not only transplant medicine but also the broader field of hematology.